CompletedPhase 2NCT02458235
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Studying Juvenile myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Christopher C Dvorak, M.D.University of California, San Francisco
- Intervention
- azacitidine(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 29 years · All sexes
- Timeline
- 2015 – 2019
Study locations (1)
- University of California San Francisco, San Francisco, California, United States
Collaborators
Hellman Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02458235 on ClinicalTrials.govOther trials for Juvenile myelomonocytic leukemia
Additional recruiting or active studies for the same condition.